<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01459627</url>
  </required_header>
  <id_info>
    <org_study_id>DAPT-STEMI</org_study_id>
    <nct_id>NCT01459627</nct_id>
  </id_info>
  <brief_title>Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI</brief_title>
  <acronym>DAPT-STEMI</acronym>
  <official_title>Prospective, Randomized, Open Label Trial of 6 Months vs. 12 Months Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation In ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maasstad Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maasstad Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVE OF THE STUDY: To test the hypothesis that 6 months DAPT (Dual anti-platelet
      therapy) after second generation DES (Drug Eluting Stent) implantation in STEMI (ST elevation
      Myocardial Infarction) is not inferior to 12 months DAPT in terms of clinical outcomes
      (composite endpoint of all-cause mortality, any MI, any revascularization, stroke and major
      bleeding at 18 months after randomization).

      The trial will incorporate two registers studying respectively the safety outcomes of
      Bivalirudin and Prasugrel combination and Bivalirudin and Ticagrelor combination at 2 and 30
      days. Finally the trial design permits assessment of the clinical outcomes after primary PCI
      for treatment of STEMI with the new Resolute Integrity (Medtronic Santa Rosa Ca, USA) stent
      at 30 days and 6 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND OF THE STUDY: First generation DES (Drug Eluting Stents) have significantly
      reduced the restenosis rates compared to the BMS (Bare Metal Stents) but have raised concerns
      regarding higher rates and ongoing propensity for stent thrombosis. Based on these concerns
      current guidelines advocate dual antiplatelet therapy (DAPT, aspirin plus P2Y12 inhibitor) to
      be continued for up to 1 year after DES implantation. Large registries analyzing recent data
      now challenge these recommendations and suggest no increase in mortality or (late) stent
      thrombosis when DAPT is discontinued after 6 months.

      STUDY DESIGN: This is a prospective, randomized, open-label trial testing the hypothesis that
      6 months DAPT after second generation drug eluting stent (DES) implantation in STEMI is not
      inferior to 12 months DAPT in terms of clinical outcomes. Patients with STEMI undergoing
      primary PCI will be enrolled at presentation. Only those patients who are event-free (death,
      MI, ST, TVR/TLR or unscheduled revascularization with DES in the first 6 months and stroke or
      bleeding requiring discontinuation of DAPT) and on DAPT at 6 months after primary PCI will be
      randomized (1:1 fashion) between single (aspirin) versus dual antiplatelet therapy (aspirin
      plus P2Y12) for an additional 6 months (up to 12 months after primary PCI) and assessed at 18
      months post randomization.

      STUDY POPULATION: Patients between 18 and 85 years, presenting with STEMI undergoing PCI with
      DES implantation.

      INTERVENTION: Patients, who are event-free and stil on DAPT at 6 months after primary PCI
      will be randomized (1:1 fashion) between single (aspirin) versus dual antiplatelet therapy
      (aspirin plus P2Y12) for an additional 6 months (up to 12 months after primary PCI).

      PRIMARY STUDY PARAMETERS/OUTCOME OF THE STUDY:

      DAPT STEMI trial Composite endpoint of all cause mortality, any MI, any revascularization,
      stroke, ST and Bleeding (TIMI) (net MACCE) at 18 months after randomization.

      Registry Bivalirudin/Prasugrel and Bivalirudin/Ticagrelor All cause mortality, MI, Stroke, ST
      and bleeding (following BARC) at 2 and 30 days.

      Report Resolute Integrity Primary endpoint of DAPT-STEMI, at 30 days and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Net MACCE</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI trial: Composite endpoint of all cause mortality, any myocardial infarction (MI) , any revascularization, stroke and major bleeding (TIMI) (net MACCE) at 18 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, MI, Stroke, ST and bleeding</measure>
    <time_frame>2 days</time_frame>
    <description>Primary outcome of Registry: All cause mortality, MI, Stroke, ST and Bleeding(following BARC)at 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, MACCE, TIMI</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: All cause mortality, any MI, stroke, stent thrombosis (ST) and major bleeding (TIMI) at 9 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST definite/probable</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: ST definite/probable academic research consortium (ARC) definition at 9 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: All cause mortality at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Cardiac mortality at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Any MI at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Target vessel MI at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Bleeding at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Stroke at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Target vessel revascularization (TVR) at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Target lesion revascularization (TLR) at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT STEMI: Target vessel failure (TVF) at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>9 months</time_frame>
    <description>DAPT-STEMI: Target lesion failure (TLF), at 9 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>net MACCE</measure>
    <time_frame>30days</time_frame>
    <description>Primary endpoint of Report Resolute Integrity: Composite endpoint of all cause mortality, any myocardial infarction (MI) , any revascularization, stroke and major bleeding (TIMI) (net MACCE) at 30 days after randomization.
Secondary endpoints of Report Resolute Integrity: Secondary endpoints of DAPT-STEMI at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, MI, Stroke, ST and bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Primary outcome of registry: All cause mortality, MI,Stroke, ST and Bleeding (following BARC) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>net MACCE</measure>
    <time_frame>6 months</time_frame>
    <description>Primary endpoint of Report Resolute Integrity: Composite endpoint of all cause mortality, any myocardial infarction (MI) , any revascularization, stroke and major bleeding (TIMI) (net MACCE) at 6 months after randomization.
Secondary endpoints of Report Resolute Integrity: Secondary endpoints of DAPT-STEMI at 6 monthss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality, MACCE, TIMI</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: All cause mortality, any MI, stroke, stent thrombosis (ST) and major bleeding (TIMI) at 18 months after randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST definite/probable</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: ST definite/probable academic research consortium (ARC) definition at 18 months post randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: All cause mortality at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Cardiac mortality at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MI</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Any MI at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Target vessel MI at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Bleeding at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Stroke at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Target vessel revascularization (TVR) at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Target lesion revascularization (TLR) at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT STEMI: Target vessel failure (TVF) at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure</measure>
    <time_frame>18 months</time_frame>
    <description>DAPT-STEMI: Target lesion failure (TLF), at 18 months after randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST following ARC</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: ST following ARC definition at 2 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ST following ARC</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: ST following ARC definition at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: All cause mortality at 2 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: All cause mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac mortality</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: Cardiac Mortality at 2 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: Cardiac Mortality at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: All MI at 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All MI</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: All MI at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: Target vessel MI at 2 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel MI</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: Target vessel MI at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding BARC</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: Bleeding (BARC) at 2 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding (BARC)</measure>
    <time_frame>30 days</time_frame>
    <description>Registry: Bleeding (BARC) at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>2 days</time_frame>
    <description>Registry: Stroke at 2 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>6 months DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be discontinued after randomisation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>12 months DAPT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual antiplatelet therapy consisting of aspirin (ASA) and prasugrel or ticagrelor will be continued till 12 months after enrollment in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>6 months DAPT</intervention_name>
    <description>Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.</description>
    <arm_group_label>6 months DAPT</arm_group_label>
    <other_name>ticagrelor, prasugrel, ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>12 months DAPT</intervention_name>
    <description>Dual antiplatelet therapy will be continued till 12 months after enrollment in the study</description>
    <arm_group_label>12 months DAPT</arm_group_label>
    <other_name>ticagrelor, prasugrel, ASA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        STEMI patients between 18-85 years who underwent primary PCI with DES implantation.

        Exclusion criteria enrolment:

          -  Intolerance to Aspirin, Prasugrel, Ticagrelor, Heparin, Bivalirudin, Zotarolimus or
             Everolimus.

          -  Known bleeding diathesis or known coagulopathy.

          -  Planned elective surgical procedure necessitating interruption of dual antiplatelet
             therapy during the first 6 months after randomization.

          -  History of stent thrombosis

          -  DES in main left coronary artery

          -  Active bleeding, known bleeding diathesis or known coagulopathy.

          -  Planned elective surgical procedure necessitating interruption of dual antiplatelet
             therapy during the first 6 months after randomization.

          -  Oral anticoagulant therapy with Coumadin derivates

          -  Malignancies or other comorbidity with a life expectancy of less than one year or that
             may result in protocol noncompliance

          -  Pregnancy (present, suspected or planned) or positive pregnancy test (in women with
             childbearing potential a negative pregnancy test is mandatory)

        Exclusion criteria randomization:

          -  Occurrence of death, myocardial infarction, stent thrombosis and target vessel or
             lesion revascularization during the first 6 months after inclusion.

          -  Stroke or bleeding requiring discontinuation of DAPT during the first 6 months after
             inclusion.

          -  Oral anticoagulant therapy

        Registry

        Exclusion criteria

          -  Intolerance to Prasugrel, Ticagrelor, Bivalirudin.

          -  Known bleeding diathesis or known coagulopathy

        Report Resolute Integrity Exclusion criteria

        • See exclusion criteria enrollment DAPT-STEMI protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elvin Kedhi, MD PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin van der Ent, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maasstadhospital / MCR B.V.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clemens von Birgelen, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Medisch Spectrum Twente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Zijlstra, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Erasmus Medisch Centrum</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VU medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atrium MC Parkstad</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstadhospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haga Hospital</name>
      <address>
        <city>The Hague</city>
        <zip>2512VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Clinics</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amerykańskie Kliniki Serca</name>
      <address>
        <city>Bielsko-Biala</city>
        <zip>43316</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Małopolskie Centrum Sercowo-Naczyniowe PAKS</name>
      <address>
        <city>Chrzanów</city>
        <zip>32500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko-Amerykańskie Kliniki Serca</name>
      <address>
        <city>Dąbrowa Górnicza</city>
        <zip>41300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko_Amerykanskei Kliniki Serca</name>
      <address>
        <city>Kedzierzyn Kozle</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital in Krakow</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polsko_Amerykanskei Kliniki Serca</name>
      <address>
        <city>Nysa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cantonal Fribourg</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2011</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAPT- Dual Antiplatelet Therapy</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

